The two most widely tested EBV-related antibodies, IgA against early antigen antibody (EA-IgA) and IgA against viral capsid antigen IgA (VCA-IgA), have been widely used for assisting in diagnosis and predicting the prognosis of NPC [8, 12, 13]. Here, CD79A is linked to nasopharyngeal carcinoma.